摘要
目的探索布美他尼在抑制肿瘤细胞增殖中的应用。方法采用免疫印迹杂交技术,验证不同肿瘤细胞中钠钾氯协同转运蛋白1(NKCC1)的表达情况;运用CCK-8法,测定布美他尼对不同肿瘤细胞的IC50值。结果肺癌细胞系(A549)、结直肠癌细胞系(HCT116)中靶蛋白NKCC1表达量显著高于慢性粒细胞白血病细胞系(K562)、食管癌细胞系(Eca109)、宫颈癌细胞系(He La)、T淋巴细胞白血病细胞系(Jurkat)和乳腺癌细胞系(MCF7);布美他尼对A549、HCT116的IC50值明显低于K562、Eca109、He La、Jurkat和MCF7,且其抑制率与靶蛋白NKCC1的表达量呈正相关。结论布美他尼能抑制肿瘤细胞增殖,NKCC1可作为潜在的抗肿瘤药物作用靶点。
Objective To explore the application of bumetanide to inhibition of tumor cell proliferation. Methods In different cell lines,the expression of natrium,kalium,chloride cotransporter 1（ NKCC1） was detected by Western blotting while the proliferation of different tumor cells was examined by CCK-8 kit. Results The target protein NKCC1 expression in lung cancer cell line（ A549） and colorectal cancer cell line（ HCT116） was significantly higher than that in chronic myelogenous leukemia cell line（ K562）,esophageal cancer cell line（ Eca109）,cervical carcinoma cell line（ He La）,T lymphocytic leukemia cell line（ Jurkat） and breast cancer cell line（ MCF7）. IC50 Values of bumetanide were significantly lower in A549 and HCT116 than in K562,Eca109,He La,Jurkat and MCF7. Furthermore,the inhibiory rate and the target protein expression level were positively correlated. Conclusion Bumetanide can inhibit tumor cell proliferation and NKCC1 can serve as a potential target of anticancer drugs.
出处
《军事医学》
CAS
CSCD
北大核心
2015年第7期495-498,共4页
Military Medical Sciences
基金
国家“重大新药创制”科技重大专项资助项目(2012ZX09301-002)
